National Cooperative Growth Study in CKD

Overview

The purpose of this study is to learn whether growth hormone being administered to children with Chronic Kidney Disease is effective and if it has any side effects.

Full Title of Study: “National Cooperative Growth Study of Nutropin AQ, Nutropin, Protropin, and Nutropin Depot in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End-Stage Renal Disease (ESRD)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 2010

Clinical Trial Outcome Measures

Primary Measures

  • The primary outcome measures of the NCGS are ongoing safety and efficacy of Genentech GH preparations in pediatric growth disorders for which GH is initiated.
    • Time Frame: per the study, the pt will be on GH treatement until the physician instructs them to stop

Participating in This Clinical Trial

Inclusion Criteria

  • Must be a patient of the UC Davis Medical Center pediatric clinic with Chronic Kidney Disease Exclusion Criteria:

  • Greater than 18 years old – Not a patient at the UC Davis Medical Center pediatric clinic

Gender Eligibility: All

Minimum Age: 1 Day

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of California, Davis
  • Collaborator
    • Genentech, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Lavjay Butani, M.D., Principal Investigator, University of California, Davis

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.